Oxygenation Circuit Devices Find A Class II Home With FDA
This article was originally published in The Gray Sheet
Executive Summary
The agency issued a final order reclassifying and renaming membrane lung devices to acknowledge their role as one component of a larger extracorporeal membrane oxygenation (ECMO) system. The decision follows 2013 and 2014 advisory panel recommendations.
You may also be interested in...
Breathing Easy: ALung CEO Talks Novel Hemolung Device, FDA's Breakthrough Pathway, Landmark US/UK Clinical Trials
In a deep-dive sit-down interview with Medtech Insight, ALung Technologies CEO Pete DeComo dishes on US FDA's Breakthrough Devices Program and explains why his firm's novel artificial lung device, Hemolung, is worthy of traveling the expedited pathway to agency approval. DeComo also details two pivotal Hemolung clinical trials in the US and UK, and explains why Hemolung isn't marketing the device for commercial use despite being approved in 36 countries outside the US. He also talks about a future portable version of Hemolung, but noted that's not where ALung is focused right now. "Our first task is that first-generation technology – to get it to market, make it the standard-of-care, and then, if you are successful with all of that, you can do all of those wonderful other things as it relates to portability and wearability," DeComo says.
FDA Panel Supports Class II Status For Oxygenation Circuit Devices, And Two Other Categories
The Circulatory System Devices Panel supported class II, with special controls, reclassification proposals from FDA for extracorporeal membrane oxygenators; external cardiac compressors; and external pacemaker pulse generators and triple chamber pacing system analyzers. But the panel had some additional requests for further action by the agency.
FDA Orders Firms To Submit Data For 25 Pre-Amendment Device Types
FDA is requiring makers of 25 types of medical devices to submit safety and effectiveness information so the agency can decide whether to down-classify the products or require pre-market approval submissions